| Abstrakt: |
Researchers at Brigham and Women's Hospital have identified a new therapeutic strategy for triple negative breast cancer (TNBC), the most aggressive type of breast cancer. By combining two therapeutic agents, EZH2 and AKT inhibitors, they were able to induce differentiation in TNBC cells, leading to cell death similar to the natural process of involution in breast tissue. These findings, published in Nature, suggest potential benefits for TNBC patients and may pave the way for future clinical trials. The study was funded by Cancer Research UK and The Mark Foundation for Cancer Research, with senior author Karen Cichowski leading the research team. [Extracted from the article] |
